10-KPeriod: FY2006

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2006

Filed March 1, 2007For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported strong revenue growth of 16% to $739.1 million for the fiscal year ended December 30, 2006. This growth was primarily driven by its Companion Animal Group (CAG), which saw a 16.4% revenue increase, fueled by instruments, consumables, rapid assays, and laboratory services. The company also experienced robust growth in its Production Animal Segment (PAS), up 31.1%. While gross profit margins remained stable around 51.3%, operating expenses increased, partly due to the adoption of new accounting standards for share-based compensation (SFAS No. 123(R)), which impacted reported expenses and operating income margins. Despite these factors, operating income grew by 10.9% year-over-year. IDEXX continues to invest in research and development, with R&D expenses increasing to 7.3% of sales, signaling a commitment to innovation in diagnostic platforms and new tests. The company also actively pursues strategic acquisitions, notably the recent addition of the Critical Care Division of Osmetech plc for its human point-of-care diagnostics market and the planned acquisition of Institut Pourquier for its production animal diagnostics business. While facing competition and regulatory hurdles, IDEXX's diversified business model across veterinary, water, and production animal health markets, coupled with ongoing product development and strategic acquisitions, positions it for continued growth.

Key Highlights

  • 1Revenue increased by 16% to $739.1 million for the fiscal year 2006, driven by strong performance in the Companion Animal Group (CAG) and Production Animal Segment (PAS).
  • 2Companion Animal Group (CAG) revenue grew by 16.4%, with significant contributions from instruments, consumables, rapid assays, and laboratory services.
  • 3Production Animal Segment (PAS) revenue saw substantial growth of 31.1%, indicating strong demand in international livestock diagnostics.
  • 4Research and Development (R&D) expenses increased to $53.6 million (7.3% of revenue), reflecting continued investment in new product development.
  • 5The company completed strategic acquisitions, including the Critical Care Division of Osmetech plc (human point-of-care diagnostics) and announced the planned acquisition of Institut Pourquier (production animal diagnostics).
  • 6Adoption of SFAS No. 123(R) for share-based compensation starting in 2006 increased operating expenses and reduced reported operating income margins.
  • 7Cash flow from operations remained strong at $109.8 million, though impacted by changes in inventory and a shift in accounting for tax benefits from stock options.

Frequently Asked Questions

IDEXX primarily operates through three reportable segments: the Companion Animal Group (CAG) focusing on veterinary diagnostics and services, the Water quality testing products segment, and the Production Animal Segment (PAS) for livestock health diagnostics. They also have a smaller 'Other' category that includes dairy quality products and recently added the OPTI Medical Systems segment for human point-of-care diagnostics.

IDEXX differentiates its veterinary diagnostic products by offering an integrated suite of instruments (IDEXX VetLab®) and consumables, rapid assay tests (SNAP®), reference laboratory services, practice information management systems (Cornerstone®), and digital radiography. Key differentiators include ease of use, speed, accuracy, breadth of diagnostic menu, integration capabilities, and superior customer service, often commanding premium pricing.

Key risks include the potential inability to maintain growth rates, adverse effects of government regulations on product marketing and sales, dependence on a limited number of suppliers for critical components, potential profitability issues from minimum purchase obligations, risks associated with veterinary pharmaceutical product sales, complexity in manufacturing biologic products, vulnerability to patent expirations and intellectual property challenges, unpredictable distributor purchasing patterns, increased competition and technological advancements by rivals, changes in testing trends, consolidation of veterinary hospitals impacting sales, inexperience in the human point-of-care market, and risks associated with international operations.

The adoption of SFAS No. 123(R) for share-based compensation, effective January 1, 2006, required the expensing of stock options and other equity awards. This resulted in an increase in reported operating expenses and a corresponding decrease in operating income margins. Specifically, it added approximately $9.0 million to operating expenses and reduced the reported operating income percentage by 1% in 2006.